Logo image of CLRB

CELLECTAR BIOSCIENCES INC (CLRB) Stock Fundamental Analysis

NASDAQ:CLRB - Nasdaq - US15117F8077 - Common Stock - Currency: USD

0.3114  -0.02 (-6.88%)

After market: 0.302 -0.01 (-3.02%)

Fundamental Rating

2

CLRB gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. While CLRB seems to be doing ok healthwise, there are quite some concerns on its profitability. CLRB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CLRB had negative earnings in the past year.
CLRB had a negative operating cash flow in the past year.
In the past 5 years CLRB always reported negative net income.
CLRB had a negative operating cash flow in each of the past 5 years.
CLRB Yearly Net Income VS EBIT VS OCF VS FCFCLRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

CLRB has a Return On Assets of -133.20%. This is amonst the worse of the industry: CLRB underperforms 82.77% of its industry peers.
With a Return On Equity value of -300.20%, CLRB is not doing good in the industry: 75.67% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -133.2%
ROE -300.2%
ROIC N/A
ROA(3y)-170.62%
ROA(5y)-130.52%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLRB Yearly ROA, ROE, ROICCLRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K 2K 3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLRB Yearly Profit, Operating, Gross MarginsCLRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

CLRB has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CLRB has more shares outstanding
CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLRB Yearly Shares OutstandingCLRB Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
CLRB Yearly Total Debt VS Total AssetsCLRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

CLRB has an Altman-Z score of -12.84. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.
CLRB's Altman-Z score of -12.84 is on the low side compared to the rest of the industry. CLRB is outperformed by 80.11% of its industry peers.
There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -12.84
ROIC/WACCN/A
WACCN/A
CLRB Yearly LT Debt VS Equity VS FCFCLRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 1.77 indicates that CLRB should not have too much problems paying its short term obligations.
The Current ratio of CLRB (1.77) is worse than 79.75% of its industry peers.
CLRB has a Quick Ratio of 1.77. This is a normal value and indicates that CLRB is financially healthy and should not expect problems in meeting its short term obligations.
CLRB has a worse Quick ratio (1.77) than 78.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.77
Quick Ratio 1.77
CLRB Yearly Current Assets VS Current LiabilitesCLRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 37.98% over the past year.
EPS 1Y (TTM)37.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.81%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CLRB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.55% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y44.47%
EPS Next 2Y32.76%
EPS Next 3Y18.42%
EPS Next 5Y12.55%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLRB Yearly Revenue VS EstimatesCLRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
CLRB Yearly EPS VS EstimatesCLRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CLRB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLRB Price Earnings VS Forward Price EarningsCLRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLRB Per share dataCLRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as CLRB's earnings are expected to grow with 18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.76%
EPS Next 3Y18.42%

More info and screens

0

5. Dividend

5.1 Amount

CLRB does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (2/21/2025, 8:10:02 PM)

After market: 0.302 -0.01 (-3.02%)

0.3114

-0.02 (-6.88%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-18 2024-11-18/bmo
Earnings (Next)03-04 2025-03-04/amc
Inst Owners11.06%
Inst Owner Change-97.21%
Ins Owners1.54%
Ins Owner Change0%
Market Cap14.35M
Analysts82
Price Target5.78 (1756.13%)
Short Float %5.2%
Short Ratio0.73
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)43.1%
Min EPS beat(2)-5.28%
Max EPS beat(2)91.47%
EPS beat(4)1
Avg EPS beat(4)13.12%
Min EPS beat(4)-28.79%
Max EPS beat(4)91.47%
EPS beat(8)3
Avg EPS beat(8)6.13%
EPS beat(12)5
Avg EPS beat(12)3.83%
EPS beat(16)8
Avg EPS beat(16)5.71%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-57.23%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0.7%
EPS NY rev (1m)0%
EPS NY rev (3m)9.89%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-0.7
Fwd EYN/A
FCF(TTM)-1.01
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS0.36
TBVpS0.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -133.2%
ROE -300.2%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-170.62%
ROA(5y)-130.52%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 103.89%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.77
Quick Ratio 1.77
Altman-Z -12.84
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)231.93%
Cap/Depr(5y)150.81%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.98%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.81%
EPS Next Y44.47%
EPS Next 2Y32.76%
EPS Next 3Y18.42%
EPS Next 5Y12.55%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-52.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-106.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-107.29%
OCF growth 3YN/A
OCF growth 5YN/A